Effect of sildenafil (Viagra) on cerebral blood flow velocity: a pilot study

Sildenafil (Viagra) is a selective inhibitor of the cyclic guanosine monophosphate (cGMP) specific phosphodiesterase 5 (PDE5) used for the oral treatment of male erectile dysfunction due to vasodilation. However, assessment of direct effects of sildenafil on cerebral arteries is unknown. The aim of this present experiment is to measure the possible changes in blood flow velocity of the middle cerebral artery after the administration of sildenafil and a placebo. Blood-flow velocity changes of the middle cerebral artery were measured before and 1 to 2 h after the administration of the drug. Neither the intake of sildenafil nor the application of placebo resulted in any significant changes in blood flow velocity of the right middle cerebral artery. The next step for future experiments will be in vitro measurement of the diameters of the cerebral arteries under the influence of sildenafil and in vivo measurement of carbon dioxide and cerebral blood flow velocity during sexual stimulation after sildenafil intake instead of under resting conditions.